Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > CG0070 + Pembrolizumab...Not even close to TLT-Ruvidar.

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Dec 14, 2023 9:54am

169 Views

Post# 35784213

RE:CG0070 + Pembrolizumab...Not even close to TLT-Ruvidar.

wildbird1 wrote: I am still on my holiday break, but could not resist to give my point of view on CG0070+Pembrolizumab.

It never cease to amaze me how some posters do not take the time to research the treatment that they say will compete with TLT-Ruvidar.

In this link...
https://mayo.edu/research/clinical-trials/cls-20508002#eligibility

In this link under "Participation Eligibility", there is a small red box that say "show more eligibility criteria".
If you look at the "exclusion criteria".
You come to the conclusion that except for having BCG resistant bladder cancer, the patient in order to receive CG0070+Pembrolizumab has to be almost in perfect health.

In short ...
If TLT-Ruvidar was treating the same kind of patients as CG0070+Pembrolizumab(with the same exclusion criteria), TLT-Ruvidar could easily have a 80-90% CR over 12 months.You have to remember that TLT-Ruvidar treat all patients without restrictions and as a bonus has side effects.

I am going back on my holiday break(will be back in 2024 unless ???), for the posters that bring on these kind of false competitors to TLT-Ruvidar, please take the time to google it first.